JPRN-jRCT2080221358未知2 期
A Randomized, Double Blind, Parallel-Group Comparison Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 50age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Diagnostic evidence of probable Alzheimer's disease (AD) consistent with the Diagnostic and Statistical Manual for Mental Disorders-version IV (DSM-IV)
- •2) Hachinski Ischemic Score -< 6
- •3) Functional Assessment Staging (FAST) scale >- 6 at Screening
- •4) Mini-Mental State Examination (MMSE) score of 1 to 12 at Screening
- •5) Subjects who are on a stable Aricept® dose of 10 mg immediate release (IR), taken as a single, daily dose for ≥ 3 months prior to the Screening Visit
- •6) Evidence consistent with Alzheimer's disease (AD) on any cranial image on magnetic resonance imaging (MRI) or computed tomography (CT) scan or etc. obtained within 24 months prior to the Screening Visit. Subjects who have any observations of dementia other than Alzheimer's type after the last image diagnosis should be reconfirmed
- •7) Age >- 50 years
- •8) Written informed consent is to have been obtained from the subject (if possible) or from the subject's legal guardian or other representative
排除标准
- •1) Subjects with dementia other than Alzheimer's type
- •2) Subjects with significant neurological or psychiatric disorders such as stroke, brain tumor, schizophrenia, epilepsy, normal pressure hydrocephalus, mental retardation, a history of head injury with loss of consciousness, or a history of brain surgery followed by persistent deficits
- •3) Subjects with allergy to donepezil hydrochloride or piperidine derivatives.
- •4) Subjects with a cause of Alzheimer's disease (AD) which is supported by any laboratory tests such as Vitamin B12, folate levels, triiodothyronine, free triiodothyronine, thyroxine, thyroid stimulating hormone (TSH) or serologic test for syphilis
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-ATJanssen-Cilag International N.V.1,100
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-EEJanssen-Cilag International N.V.1,050
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaSchizophreniaEUCTR2006-003560-62-HUJanssen-Cilag International N.V.700
进行中（未招募）
1 期
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaEstudio Comparativo, Aleatorizado, Doble-Ciego, de Grupos Paralelos entre Diferentes Dosis de Palmitato de Paliperidona y de Risperidona Intramuscular Inyectable de Larga Duración en Sujetos con EsquizofreniaMedDRA version: 9.1Level: LLTClassification code 10039626Term: SchizophreniaSchizophreniaEUCTR2006-003560-62-ESJanssen-Cilag International N.V.
进行中（未招募）
不适用
A Randomized, Double-Blind, Parallel-Group, Comparative Study of FlexibleDoses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-ActingIntramuscular Injection in Subjects with SchizophreniaSchizophreniaEUCTR2006-003560-62-DEJanssen-Cilag International N.V., Turnhoutseweg 30, 2340 Beerse, Belgium1,100